ANTARES PHARMA, INC. — Revenue by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/cd2899c8-3739-4a58-9c31-e0da9d11fb01/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2021 | $184.0M | 2021-01-01 – 2021-12-31 | evidence 0001016169-22-000028 |
| FY 2020 | $149.6M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-010298 |
| FY 2019 | $123.9M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-008465 |
| FY 2018 | $63.6M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-007398 |
| FY 2017 | $54.5M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-007398 |
| FY 2016 | $52.2M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-007398 |
| FY 2015 | $27.5M | 2015-01-01 – 2015-12-31 | evidence 0001564590-18-005459 |
| FY 2014 | $13.2M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-088373 |
| FY 2013 | $11.0M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-097968 |
| FY 2012 | $9.1M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-105398 |
| FY 2011 | $7.6M | 2011-01-01 – 2011-12-31 | evidence 0001016169-12-000005 |
| FY 2010 | $5.8M | 2010-01-01 – 2010-12-31 | evidence 0001016169-12-000005 |
| FY 2009 | $3.5M | 2009-01-01 – 2009-12-31 | evidence 0001016169-12-000005 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ANTARES PHARMA, INC. — all facts · Net Income · Operating Income